Glycoconjugates: What It Would Take To Master These Well-Known yet Little-Understood Immunogens for Vaccine Development
Fikri Avci,
Francesco Berti,
Peter Dull,
John Hennessey,
Viliam Pavliak,
A. Krishna Prasad,
Willie Vann,
Michael Wacker,
Olivier Marcq
Affiliations
Fikri Avci
Department of Biochemistry and Molecular Biology, Center for Molecular Medicine and Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia, USA
Francesco Berti
GSK Vaccines, Siena, Italy
Peter Dull
Bill and Melinda Gates Foundation, Seattle, Washington, USA
John Hennessey
Independent Researcher, Lower Gwynedd, Pennsylvania, USA
Viliam Pavliak
International Vaccines Institute (IVI), Seoul, Republic of Korea
ABSTRACT Glycoconjugate vaccines are a critical component of the medical arsenal against infectious diseases. This established field continues, however, to experience failures in the clinic. The lack of fundamental understanding of factors controlling clinical efficacy of glycoconjugate vaccines is discussed while key parameters demanding focused and collaborative research are identified.
